本文選題：金黃地鼠　切入點(diǎn)：頰癌　出處：《河北醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:口腔鱗狀細(xì)胞癌(oral squamous cell carcinoma,OSCC)是目前較多見(jiàn)的破壞性最大的癌癥之一,惡性程度高,位于口腔頜面部,手術(shù)治療是目前最常用的治療方法,但因此會(huì)造成患者面容缺損,功能障礙,嚴(yán)重影響其生活。雖然配合其他療法,患者的5年生存率仍停留在50%左右,且局部復(fù)發(fā)率極高。因此我們迫切渴望尋找到綜合有效的方法來(lái)保存患者組織器官的完整性,提高其生活質(zhì)量。現(xiàn)在有越來(lái)越多的中藥應(yīng)用到惡性腫瘤的治療當(dāng)中,都取得了不錯(cuò)的效果,而且這種趨勢(shì)有增無(wú)減。本實(shí)驗(yàn)采用中藥甘露清涼飲對(duì)建立的實(shí)驗(yàn)動(dòng)物模型口腔頰黏膜鱗癌進(jìn)行治療,觀察其是否可以抑制口腔癌的發(fā)生及發(fā)展,并對(duì)其抗腫瘤機(jī)制進(jìn)行初步探討,為今后的實(shí)驗(yàn)和臨床應(yīng)用提供實(shí)驗(yàn)理論依據(jù)。方法:實(shí)驗(yàn)對(duì)象為85只6~8周齡、體重約100 g的敘利亞金黃地鼠,雌雄兼?zhèn)?分籠喂養(yǎng),取10只為空白對(duì)照組,不作任何處理;其余75只金黃地鼠用0.3%DMBA注射右側(cè)頰囊12周,第13周時(shí)將成瘤的60只實(shí)驗(yàn)動(dòng)物采用隨機(jī)數(shù)字表法將地鼠分為3個(gè)用藥組和1個(gè)模型對(duì)照組(每組15只),低劑量甘露清涼飲組、中劑量甘露清涼飲組及高劑量甘露清涼飲組分別灌服7.5、15、30 g/kg的甘露清涼飲4周,空白對(duì)照組不做任何處理。第17周處死全部動(dòng)物,記錄肉眼腫瘤發(fā)生率、腫瘤數(shù)目及體積,腫瘤組織行HE染色鏡下觀察,用免疫組化方法檢測(cè)組織中BCL-2、CD86的表達(dá)。所有數(shù)據(jù)采用SPSS 13.0統(tǒng)計(jì)軟件,P0.05具有統(tǒng)計(jì)學(xué)意義。結(jié)果:1肉眼可見(jiàn)腫瘤發(fā)生率模型對(duì)照組為91.5%,低劑量甘露清涼飲組81.4%,中劑量甘露清涼飲組76.9%,高劑量甘露清涼飲組69.6%(P0.01);各用藥組平均腫瘤數(shù)目均較模型對(duì)照組2.43±1.55個(gè)有所降低,其中中劑量甘露清涼飲組1.47±1.04個(gè)和高劑量甘露清涼飲組1.16±1.02個(gè)顯著下降(P0.01)。2各用藥組組織病理學(xué)觀察鱗狀細(xì)胞癌病變數(shù)目均較模型對(duì)照顯著降低(P0.05)。3各用藥組與模型對(duì)照組相比均能降低病損處的血管密度,尤以中、高劑量甘露清涼飲組效果更佳(P0.05)。4各用藥組免疫組化檢測(cè)BCL-2較模型對(duì)照組表達(dá)水平有所降低,高劑量組甘露清涼飲效果最為顯著(P0.05)。5各用藥組免疫組化檢測(cè)CD86均呈高表達(dá),高于模型對(duì)照組,尤以高劑量甘露清涼飲效果更佳(P0.05)。結(jié)論:1甘露清涼飲可抑制金黃地鼠頰粘膜鱗癌的生長(zhǎng),其中高劑量給藥方式抑癌作用效果最好。2甘露清涼飲可以通過(guò)減少血管新生抑制金黃地鼠頰癌的發(fā)生發(fā)展。3甘露清涼飲可能是通過(guò)下調(diào)BCL-2的表達(dá)來(lái)促進(jìn)頰癌細(xì)胞的凋亡。4上調(diào)免疫細(xì)胞CD86的表達(dá),提高腫瘤監(jiān)視功能,可能是甘露清涼飲抑癌作用的機(jī)制之一。
[Abstract]:Objective: oral squamous cell carcinoma (OSCC) is one of the most destructive cancers in oral squamous cell carcinoma. It is located in oral and maxillofacial region with a high degree of malignancy. Surgical treatment is the most commonly used method at present, but it can cause facial defects in patients. The 5-year survival rate of the patients remained at around 50%, despite the combination of other therapies. And the local recurrence rate is extremely high. Therefore, we are eager to find comprehensive and effective methods to preserve the integrity of patients' tissues and organs and improve their quality of life. Now more and more Chinese medicines are used in the treatment of malignant tumors. This experiment used mannoxingliangyin to treat oral and buccal squamous cell carcinoma, and observed whether it could inhibit the occurrence and development of oral cavity cancer. The mechanism of anti-tumor was preliminarily discussed in order to provide experimental theoretical basis for the future experiment and clinical application. Methods: 85 Syrian golden hamsters, weighing about 100g, aged 6 weeks and 8 weeks old, were fed in separate cages, both male and female. The other 75 golden hamsters were injected with 0.3DMBA for 12 weeks. At the 13th week, 60 experimental animals were randomly divided into 3 drug groups and 1 model control group (15 rats in each group, low dose mannu Qingliang decoction group). The middle dose Ganlu Qingliang decoction group and the high dose Ganlu Qingliang decoction Group were given 7.5U 1530g / kg Mannu Qingliang drink for 4 weeks respectively, and the blank control group did not do any treatment. At the 17th week, all the animals were killed and the incidence, number and volume of the tumor were recorded. The tumor tissue was observed by HE staining. The expression of BCL-2 + CD86 in tissues was detected by immunohistochemical method. All the data were statistically significant by SPSS 13.0 statistical software (P0.05). Results the incidence rate of tumor was 91.5 in the model control group and 81.4 in the low-dose Gannuqingliang Yin group, and the middle dose was found in the low dose of Gannuqingliang Yin group. The average number of tumors in the Ganlu Qingliang decoction group was lower than that in the model control group (2.43 鹵1.55), and that in the mannoxiangliang drink group (69.6) was lower than that in the model control group (P 0.01). Among them, 1.47 鹵1.04 in medium dose Ganlu Qingliang decoction group and 1.16 鹵1.02 in high dose Ganlu Qingliang decoction group were significantly decreased P0.01T.2 the number of squamous cell carcinoma lesions in each drug group was significantly lower than that in model control group and model control group (P 0.05.3). Compared with the control group, the blood vessel density in the lesion was decreased. In particular, the expression of BCL-2 in the high dose group was lower than that in the model control group. The expression of CD86 was significantly higher in the high dose group than that in the model control group. The expression of CD86 in each drug group was significantly higher than that in the high dose group (P0.055.The expression of CD86 in each group was higher than that in the control group). Compared with the model control group, the effect of high dose manlu Qingliang drink was better than that of the model control group (P 0.05). Conclusion the growth of buccal mucosa squamous cell carcinoma of golden hamster can be inhibited by W1 Ganlu Qingliang decoction. The effect of high dose administration is the best. 2. Mannoxinqingliangyin can inhibit the occurrence and development of golden hamster buccal carcinoma by reducing angiogenesis. 3 mannose Qingliang drink may promote buccal cancer cells by down-regulating the expression of BCL-2. Upregulate the expression of CD86 in immune cells, Enhancing tumor surveillance may be one of the mechanisms of manlu Qingliang Yin's anti-cancer effect.
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R285.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王軍梅;;甘露飲加減對(duì)濕熱困脾證2型糖尿病中醫(yī)證候和糖脂代謝水平的影響[J];四川中醫(yī);2015年12期

2 張風(fēng)梅;王軍敬;張巧玲;;甘露飲治療濕熱傷陰型干眼臨床觀察[J];中國(guó)中醫(yī)眼科雜志;2015年05期

3 金春花;于梅;李淑菊;張佩青;;張佩青教授治療慢性腎衰竭經(jīng)驗(yàn)舉隅[J];黑龍江中醫(yī)藥;2015年03期

4 陳燁;;淡竹葉化學(xué)成分與藥理作用研究進(jìn)展[J];亞太傳統(tǒng)醫(yī)藥;2014年13期

5 郭琳;苗明三;;生(鮮)地黃的化學(xué)、藥理與應(yīng)用特點(diǎn)[J];中醫(yī)學(xué)報(bào);2014年03期

6 李鵬飛;苗明三;;熟地黃的現(xiàn)代研究及應(yīng)用現(xiàn)狀分析[J];中醫(yī)學(xué)報(bào);2014年02期

7 張龍?chǎng)?胡晶紅;張永清;;羚羊角藥理研究概況[J];中國(guó)醫(yī)藥導(dǎo)報(bào);2013年28期

8 張瑜;武斌;許建衛(wèi);;黃芩藥理作用的研究進(jìn)展[J];醫(yī)學(xué)綜述;2013年06期

9 張春靜;;黃連藥理作用研究進(jìn)展概述[J];科技創(chuàng)新與應(yīng)用;2013年05期

10 何娜;;甘露飲和沙利度胺聯(lián)合治療復(fù)發(fā)性阿弗他潰瘍的療效評(píng)價(jià)[J];海峽藥學(xué);2012年08期

，

本文編號(hào)：1625996